Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants

Vaccine

Volumn 29, Issue 11, 2011, Pages 2079-2084

  Vesikari, T ^a   Karvonen, A ^a   Bouckenooghe, A ^b,e   Suryakiran, P V ^c   Smolenov, I ^b   Han, H H ^d  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GlaxoSmithKline Pharmaceuticals Ltd   (India)

^d GLAXOSMITHKLINE   (United States)

^e Sanofi Pasteur Research and Development   (Singapore)

Author keywords

Finnish; Liquid formulation; RIX4414; Rotavirus vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; IMMUNOGLOBULIN A; PLACEBO; ROTAVIRUS VACCINE; VIRUS ANTIBODY;

ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ANTIBODY BLOOD LEVEL; ARTICLE; BRONCHIOLITIS; BRONCHITIS; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; FEVER; FINLAND; FREEZE DRYING; GASTROENTERITIS; HUMAN; IMMUNOGENICITY; INFANT; INFANTILE SPASM; INTUSSUSCEPTION; IRRITABILITY; LARYNGITIS; MALE; MULTICENTER STUDY; OTITIS MEDIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; ROTAVIRUS INFECTION; SEROCONVERSION; SIDE EFFECT; STREPTOCOCCAL PHARYNGITIS; SUSPENSION; VOMITING;

ADMINISTRATION, ORAL; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FECES; FEMALE; FINLAND; FREEZE DRYING; GASTROENTERITIS; HUMANS; IMMUNOGLOBULIN A; INFANT; MALE; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 79951809287     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.004     Document Type: Article

References (17)

1. Nguyen T.V., Van P.L., Huy C.L., Weintraub A. Diarrhea caused by rotavirus in children less than 5 years of age in Hanoi. Vietnam J Clin Microbiol 2004, 42:5745-5750.
2. Staat M.A., Azimi P.H., Berke T., Roberts N., Bernstein D.I., Ward R.L., et al. Clinical presentations of rotavirus infection among hospitalized children. Pediatr Infect Dis J 2002, 21:221-227.
3. World Health Organization Rotavirus vaccines. WHO position paper. Wkly Epid Rec 2007, 82:285-296.
4. Mrukowicz J., Szajewska H., Vesikari T. Options for the prevention of rotavirus disease other than vaccination. J Pediatr Gastroenterol Nutr 2008, 46:S32-37.
5. Glass R.I., Parashar U.D., Bresee J.S., Turcios R., Fischer T.K., Widdowson M.A., et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006, 368:323-332.
6. Vesikari T. Rotavirus vaccines. Scand J Infect Dis 2008, 40:691-695.
7. O'Ryan M. Rotarix™ (RIX4414): an oral human rotavirus vaccine. Expert Rev Vaccines 2007, 6:11-19.
8. Bernstein D.I., Smith V.E., Sherwood J.R., Schiff G.M., Sander D.S., DeFeudis D., et al. Safety and immunogenicity of a live attenuated human rotavirus 89-12 vaccine. Vaccine 1998, 16:381-387.
9. Bernstein D.I., Sack D.A., Rothstein E., Reisinger K., Ward R.L. Efficacy of live attenuated human rotavirus vaccine 89-12 in infants. Lancet 1999, 354:287-290.
10. Bernstein D.I., Sack D.A., Reisinger K., Rothstein E., Ward R.L. Second year follow-up evaluation of live attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002, 186:1487-1489.
11. Vesikari T., Karvonen A., Korhonen T., Espo M., Lebacq E., Forster J., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004, 22:2836-2842.
12. Vesikari T., Karvonen A., Puustinen L., Zeng S.Q., Szakal E.D., Delem A., et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004, 23:937-943.
13. Linhares A.C., Velázquez F.R., Pérez-Schael I., Sáez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371:1181-1189.
14. van Doorn L.J., Kleter B., Hoefnagel E., Stainier I., Poliszczak A., Colau B., et al. Detection and genotyping of human rotavirus VP4 and VP7 genes by reverse transcriptase PCR and reverse hybridization. J Clin Microbiol 2009, 47:2704-2712.
15. Ward R.L. Mechanisms of protection against rotavirus in humans and mice. J Infect Dis 1996, 174:S1-S8.
16. Franco M.A., Angel J., Greenberg H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006, 24:2718-2731.
17. Velazquez F.R., Matson D.O., Guerrero M.L., Shults J., Calva J.J., Morrow A.L., et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000, 182:1602-1609.